Paper39875346
Seventy Years Later: Systemic and Local Properdin in Atherosclerosis.
Regal JF and 1 other. J Am Heart Assoc, 2025. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Seventy Years Later: Systemic and Local Properdin in Atherosclerosis. Papers, record 39875346. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39875346
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 39,868,499 | Alternative Complement Pathway in Carotid Atherosclerosis: Low Plasma Properdin Levels Associate With Long-Term Cardiovascular Mortality. | https://conductscience.org/library/papers/39868499 |
Source PubMed
References18
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37,662,914 | Properdin inhibition ameliorates hepatic ischemia/reperfusion injury without interfering with liver regeneration in mice. | Front Immunol | 2023 | https://conductscience.org/library/papers/37662914 | PubMed |
| 2 | 37,499,656 | Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis. | Immunity | 2023 | https://conductscience.org/library/papers/37499656 | PubMed |
| 3 | 4,134,064 | Activation of the alternate pathway of human complements by rabbit cells. | J Immunol | 1974 | https://conductscience.org/library/papers/4134064 | PubMed |
| 4 | 33,868,287 | Complement Initiation Varies by Sex in Intestinal Ischemia Reperfusion Injury. | Front Immunol | 2021 | https://conductscience.org/library/papers/33868287 | PubMed |
| 5 | 26,091,721 | The role of complement activation in atherogenesis: the first 40 years. | Immunol Res | 2016 | https://conductscience.org/library/papers/26091721 | PubMed |
| 6 | 39,868,499 | Alternative Complement Pathway in Carotid Atherosclerosis: Low Plasma Properdin Levels Associate With Long-Term Cardiovascular Mortality. | J Am Heart Assoc | 2025 | https://conductscience.org/library/papers/39868499 | PubMed |
| 7 | 31,263,464 | Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy. | Front Immunol | 2019 | https://conductscience.org/library/papers/31263464 | PubMed |
| 8 | 38,600,367 | Canonical and non-canonical roles of complement in atherosclerosis. | Nat Rev Cardiol | 2024 | https://conductscience.org/library/papers/38600367 | PubMed |
| 9 | 7,010,302 | A war with the molecules: Louis Pillemer and the history of properdin. | Perspect Biol Med | 1980 | https://conductscience.org/library/papers/7010302 | PubMed |
| 10 | 28,139,294 | C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy. | Kidney Int | 2017 | https://conductscience.org/library/papers/28139294 | PubMed |
| 11 | 4,176,223 | Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components. | J Exp Med | 1968 | https://conductscience.org/library/papers/4176223 | PubMed |
| 12 | 29,954,621 | Properdin: A multifaceted molecule involved in inflammation and diseases. | Mol Immunol | 2018 | https://conductscience.org/library/papers/29954621 | PubMed |
| 13 | 23,184,055 | Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency. | J Am Soc Nephrol | 2013 | https://conductscience.org/library/papers/23184055 | PubMed |
| 15 | 6,993,558 | Presidential address to American Association of Immunologists in Anaheim, California, April 16, 1980. Louis Pillemer, Properdin, and scientific controversy. | J Immunol | 1980 | https://conductscience.org/library/papers/6993558 | PubMed |
| 16 | 35,365,353 | The multifaceted impact of complement on atherosclerosis. | Atherosclerosis | 2022 | https://conductscience.org/library/papers/35365353 | PubMed |
| 17 | 36,713,423 | A novel assay that characterizes properdin function shows neutrophil-derived properdin has a distinct oligomeric distribution. | Front Immunol | 2022 | https://conductscience.org/library/papers/36713423 | PubMed |
| 19 | 24,667,818 | Protective role for properdin in progression of experimental murine atherosclerosis. | PLoS One | 2014 | https://conductscience.org/library/papers/24667818 | PubMed |
| 20 | 31,849,925 | Properdin: A Novel Target for Neuroprotection in Neonatal Hypoxic-Ischemic Brain Injury. | Front Immunol | 2019 | https://conductscience.org/library/papers/31849925 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39875346
GET https://conductscience.org/api/papers/v1/39875346/authors